{"url_path":"/sec/ctmx/8-k/2026-06-22/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1501989/0001193125-26-277631-index.html","accession_number":"0001193125-26-277631","cik":"0001501989","ticker":"CTMX","issuer_name":"CytomX Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501989/0001193125-26-277631-index.html","primary_entity_key":"0001501989","primary_entity_name":"CytomX Therapeutics, Inc."},"word_count":424,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nThe Company held its Annual Meeting on June 17, 2026. On April 20, 2026, the record date for the Annual Meeting, there were 217,702,919 shares of the Company’s common stock outstanding, with each such share being entitled to one vote.\n\nAt the Annual Meeting, 183,604,084 shares of the Company’s common stock were voted online or by proxy for the seven proposals set forth below, each of which is described in the Proxy Statement.\n\nProposal 1. The Company’s stockholders elected the Class II director nominees below to the Board to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal.\n\n \n\nNOMINEE\n\n  \nFOR\n \n  \nAGAINST\n \n  \nABSTAIN\n \n  \nBROKER\nNON-VOTES\n \n\nMatthew P. Young\n\n  \n \n146,742,827\n \n  \n \n2,062,471\n \n  \n \n199,664\n \n  \n \n34,599,122\n \n\nElaine V. Jones Ph.D.\n\n  \n \n131,377,301\n \n  \n \n17,428,951\n \n  \n \n198,710\n \n  \n \n34,599,122\n \n\nProposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.\n\n \n\nFOR\n\n \n\nAGAINST\n\n \n\nABSTAIN\n\n182,976,052\n \n382,681\n \n245,351\n\nAs a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.\n\nProposal 3. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares.\n\n \n\nFOR\n\n \n\nAGAINST\n\n \n\nABSTAIN\n\n178,362,995\n \n4,771,689\n \n469,400\n\nProposal 4. The Company’s stockholders approved an amendment to the 2015 Plan, as described in the Proxy Statement.\n\n \n\nFOR\n\n \n\nAGAINST\n\n \n\nABSTAIN\n\n \n\nBROKER\nNON-VOTES\n\n147,079,951\n \n1,745,001\n \n180,010\n \n34,599,122\n\nProposal 5. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Employee Stock Purchase Plan, as described in the Proxy Statement.\n\n \n\nFOR\n\n \n\nAGAINST\n\n \n\nABSTAIN\n\n \n\nBROKER\nNON-VOTES\n\n147,375,197\n \n1,468,576\n \n161,189\n \n34,599,122\n\nProposal 6. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.\n\n \n\nFOR\n\n \n\nAGAINST\n\n \n\nABSTAIN\n\n \n\nBROKER\nNON-VOTES\n\n147,127,715\n \n1,722,679\n \n154,568\n \n34,599,122\n\nProposal 7. The non-binding, advisory vote regarding the frequency of future advisory votes by stockholders on the compensation of the Company’s named executive officers:\n\n \n\n1 YEAR\n\n \n\n2 YEARS\n\n \n\n3 YEARS\n\n \n\nABSTAIN\n\n \n\nBROKER\nNON-VOTES\n\n145,004,404\n \n1,298,607\n \n2,352,377\n \n349,574\n \n34,599,122\n\nBased upon the results set forth in Proposal 7 above, the Company currently intends to hold an advisory vote on the compensation of its named executive officers every year.\n\nNo other items were presented for stockholder approval at the Annual Meeting."}